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Abstract 
Bac7 (1–35) is an Arg- and Pro-rich peptide antibiotic, produced in bovine cells to protect them from microbial infec-
tion. It has been demonstrated to inhibit the protein synthesis in E. coli, leading to cell death. Because of its toxicity, no 
cost effective methods have been developed for Bac7 production in Escherichia coli for its potential clinical use. Here, 
we found a method to suppress Bac7 (1–35) toxicity in E. coli to establish its high expression system, in which Bac7 
(1–35) was fused to the C-terminal end of protein S, a major spore-coat protein from Myxococcus xanthus, using a 
linker containing a Factor Xa cleavage site. The resulting His6-PrS2-Bac7 (1–35) (PrS2 is consisted of two N-terminal half 
domains of protein S connected in tandem) was well expressed using the Single-Protein Production (SPP) system at 
low temperature and subsequently purified in a single step by using a Ni column. The combination of protein S fusion 
and its expression in the SPP system at low temperature appeared to suppress Bac7 (1–35) toxicity. Both the purified 
His6-PrS2-Bac7 (1–35) and His6-PrS2-Bac7 (1–35) treated by Factor Xa were proven to be a potent inhibitor for cell-free 
protein synthesis.
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Introduction
Antimicrobial peptides (AMPs) consisting of 10–50 amino 
acid residues have been discovered from insects to mam-
mals, specifically targeting against either Gram-nega-
tive bacteria or Gram-positive bacteria or both (Daher 
et al. 1988; Xi et al. 2014; Jayamani et al. 2015). Some of 
them are fungicidal. Some AMPs form helical structures 
through the membrane to cause cell lysis in a broad range 
of micro-organisms (Jamasbi et  al. 2014; Li et  al. 2015), 
while the others having very high contents of proline and 
arginine residues inhibit the functions of essential intra-
cellular components (Tu et  al. 2011; Roy et  al. 2015). As 
recent emergence of highly antibiotic-resistant or multi-
drug resistant pathogens, AMPs have become attractive 
alternatives for the treatment of patients. The use of AMPs 
is considered to be somehow less problematic than the 
use of conventional antibiotics as AMPs induce resistant 
strains in a much lower frequency (Zasloff 2002; Perron 
et al. 2006). Furthermore, the use of AMPs together with 
conventional antibiotics may have synergistic effects for 
therapeutic purpose. On the other hand, the disadvantages 
of AMPs are their cytotoxicity to the host, their instability 
in the cells, and the cost of their synthesis. Among AMPs, 
proline-rich antimicrobial peptides (PR-AMPs) have been 
isolated from mammalian neutrophils and from haemo-
lymph of some invertebrate species (Anderson and Yu 
2003; Treffers et al. 2005; Paulsen et al. 2013).
Bac7 (1–35) is a PR-AMP isolated from bovine and 
belongs to the cathelicidin family (Scocchi et  al. 1997). 
The cathelicidins serve a critical role in mammalian 
innate immune defense against invasive bacterial infec-
tion (Zanetti 2004), and Bac7 (1–35) was found from 
bovine neutrophils together with cathelicidin as a anti-
microbial peptides (Romeo et  al. 1988; Gennaro et  al. 
1989). Later, Bac7 (1–35) was shown to inhibit DNA, 
RNA, and protein synthesis in E. coli (Mardirossian 
et al. 2014) after penetrating in the cells through SmbA, 
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a peptide transporter (Mattiuzzo et  al. 2007). Recently, 
Bac7 (1–35) was shown to bind to 70S ribosome result-
ing in inhibition of protein synthesis (Mardirossian et al. 
2014). Despite the high toxicity to Gram-negative bac-
teria such as E. coli, Klebsiella pneumoniae, Salmonella 
typhimurium, and Enterobacter cloacae at 1–10 μM, Bac7 
(1–35) has remarkably low cytotoxicity to the host mam-
malian cells (not toxic even at 50 μM) (Tomasinsig et al. 
2006). Therefore, Bac7 (1–35) has been extensively stud-
ied because of its potential use for clinical application. A 
method to stabilize Bac7 (1–35) by PEGylation has been 
developed to reduce its renal clearance by which Bac7 
(1–35) still retains its antibacterial activity as well as cell 
penetration activity (Benincasa et al. 2015).
For pharmaceutical applications, development of a 
method for an efficient AMP synthesis is important, but no 
successful expression system for Bac7 (1–35) has reported. 
So far, the production of some AMPs has been success-
fully carried out with a yeast system since these AMPs are 
not toxic to yeast (Jiménez et al. 2014; Wang et al. 2014; 
Mao et al. 2015). Furthermore, some AMPs have been pro-
duced using an E. coli system in combination with fusion 
tags such as thioredoxin (Feng et  al. 2012) glutathione 
S-transferase (GST) (Feng et  al. 2014), maltose-binding 
protein (MBP) (Velásquez et al. 2011) and small ubiquitin-
like modifier like protein (SUMO) and subsequent cleav-
age of the AMPs form the fusion proteins by proteases 
such as thrombin, tobacco etch virus NIa protease, bovine 
coaglulation factor Xa, and enterokinase, which recognize 
only short, linear peptide sequences. However, if the AMP 
activity can be retained without cleavage from the fusion 
construct, it would be so much convenient for the toxicity 
assay of the AMPs. For this purpose, the SUMO technol-
ogy has been successfully applied to many AMPs such as 
plectasin (Zhang et al. 2015), cathelicidin (Luan et al. 2014) 
and CM4 (Li et al. 2011).
In the present paper, we attempted to express Bac7 
(1–35) in E. coli cells. Since Bac7 (1–35) is highly toxic 
to E. coli, it is essential to suppress its toxicity for its pro-
duction. For this purpose, we tested two different protein 
tags, SUMO and protein S from Myxococcus xanthus 
to examine if the fusion tags could reduce the toxic-
ity and enhance the expression of Bac7 (1–35). Protein 
S is a major spore-coat protein, which has been used as 
an effective fusion tag (Kobayashi et al. 2009). Protein S 
consists of 173 amino acids, which is composed of two 
homologous domains, the 92-residue N-terminal and the 
81-residue C-terminal domains (Bagby et  al. 1994). The 
expression vector, pCold-PST, contains two N-terminal 
domains (PrS2), repeated in tandem, to the C-terminal 
end of which a cloned protein or peptide is fused. pCold-
PST vector has been shown to enhance the expression as 
well as the solubility of a cloned protein (Kobayashi et al. 
2009). Protein S fused to a target protein has been shown 
not to severely affect the structure and function of the 
protein to be fused (Kobayashi et  al. 2009, 2012). Since 
AMPs are toxic to the cells when expressed in E. coli, the 
suppression of toxicity to the cells possibly is essential for 
the production of AMPs. For this purpose, we attempted 
to use the Single-Protein Production (SPP) system for the 
production of PrS2-Bac7 (1–35), in which MazF, an ACA-
specific endoribonuclease from E. coli is induced to elim-
inate almost all cellular mRNAs except for the mRNA 
for His6-PrS2-Bac7 (1–35) that is designed to have no 
ACA sequences without altering its amino acid sequence 
(Zhang et al. 2003; Suzuki et al. 2005, 2006). This enables 
us to produce only His6-PrS2-Bac7 (1–35) in E. coli cells 
without producing any other cellular proteins. Indeed, 
we were able to produce His6-PrS2-Bac7 (1–35) in a rea-
sonable amount in E. coli cells, while with the SUMO tag, 
we were unable to express the protein.
Materials and methods
Construction of pColdPrS2Bac7 (1–35) vector 
and pColdSUMOBac7 (1–35)
A codon optimized ACA-less Bac7 (1–35) gene (cgtcg-
tattcgtccgcgtccaccgcgtctgccgcgtccgcgcccgcgtccactgc-
cgttcccacgtccaggtccgcgtccgattccacgtccgctgccattcccgtaa) 
was synthesized (IDT) and cloned into ACA-less pCold-
PrS2 (Takara Bio) by using an infusion cloning system 
(Clontech), generating pColdPrS2-Bac7 (1–35), which is 
capable to produce His6-PrS2-Bac7 (1–35). PrS2 consists 
of two N-terminal half domains of protein S repeated in 
tandem (Kobayashi et al. 2009, 2012). His6-PrS2 and Bac7 
(1–35) was linked with a tetra peptide, Ile-Glu-Gly-Arg 
as the Factor Xa cleavage site. Factor Xa cleaves the pep-
tide after Arg so that intact Bac7 (1–35) is released after 
Factor Xa treatment without any extra amino acid resi-
dues attached.
The codon-optimized ACA-less SUMO-Bac7 (1–35) 
gene was synthesized (IDT) and cloned into pColdII 
(Takara Bio) by using infusion cloning system (Clontech), 
generating pColdSUMOBac7 (1–35) vector. In order 
to produce Bac7 (1–35) as a fusion protein, BL21(DE3) 
cells transformed with either pColdPrS2-Bac7 (1–35) or 
pColdSUMO-Bac7 (1–35) were inoculated into 10  ml 
of LB medium and the culture was incubated at 37  °C. 
When OD600 reached 0.8, the culture was transferred to 
15 °C and the fusion proteins were induced by the addi-
tion of 1 mM IPTG. The mixture was further incubated 
for overnight.
Production and purification of His6‑PrS2‑Bac7 (1–35) using 
SPP system
BL21(DE3) co-transformed with pACYCmazF and 
pColdPrS2-Bac7 (1–35) was inoculated into 1  l of LB 
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medium and the culture was incubated at 37  °C. When 
the OD600 reached 0.8, the culture was chilled on ice for 
5  min, followed by incubation at 15  °C for another 1  h. 
Subsequently, 1  mM IPTG was added to induced MazF 
and the culture was incubated at 15  °C for overnight 
(Suzuki et al. 2006). The cells were collected by centrifu-
gation and re-suspended into 20  ml of binding/washing 
buffer consisting of 20 mM Tris–HCl (pH 8.0), 500 mM 
NaCl, and 20 mM imidazole–HCl (pH 8.0). After break-
ing the cells by using a French press, the unbroken 
cells were removed by centrifugation at 14,000  rpm for 
20  min. The supernatant thus obtained was subjected 
to further centrifugation at 50,000  rpm for 30  min to 
remove the membrane fraction. The supernatant fraction 
was mixed with 1  ml of Ni-resin equilibrated in bind-
ing/wash buffer and the mixture was incubated for 1 h at 
4 °C. The Ni-resin was washed twice with 10 ml of wash-
ing buffer, and His6-PrS2-Bac7 (1–35) was eluted with 
20 mM Tris–HCl (pH8), 500 mM NaCl and 300 mM imi-
dazole–HCl (pH8.0). After collecting the eluted protein, 
the protein concentration was determined by the optical 
density at 280 nm using Nano Drop (Thermo Scientific), 
and the purity was examined by SDS-PAGE. After the 
protein fraction was dialyzed against 20  mM Tris–HCl 
(pH8.0) and 100 mM NaCl, it was concentrated to 3 mg/
ml and stored at −80 °C.
Cleavage by factor Xa and identification of Bac7 (1–35)
The 30  μg of His6-PrS2-Bac7 (1–35) was digested with 
4  μg of factor Xa in a 50  μl mixture containing 20  mM 
Tris–HCl (pH 8.0). 50 mM NaCl and 2 mM CaCl2. The 
reaction mixture was then incubated for 4 h at 37 °C, and 
the cleavage product was analyzed by 19  % SDS-PAGE 
followed by Coomassie blue staining. In order to con-
firm Bac7 (1–35) by mass spectrometry, His6-PrS2-Bac7 
(1–35) was cleaved by factor Xa protease and the reaction 
mixture was diluted 25 times by the matrix solution con-
taining sinapinic acid (10  mg/ml) in 0.1  % trifloroacetic 
acid and 50  % acetonitrile) and spotted on to a target 
plate (Opti-TOF 384 well insert, ABSciex) and air dried, 
followed by mass spectrometric analysis by a MALDI-
TOF (4800 MALDI-TOF/TOF, ABSciex) using the posi-
tive mid-mass linear mode from 2 to 30 kDa.
Small scale purification of Bac7 (1–35) by ion‑exchange 
column chromatography
Three hundred sixty μg of His6-PrS2-Bac7 (1–35) was 
digested with 5 μg of factor Xa in a 500-μl of 20 mM Tris–
HCl (pH 8.0) containing 50 mM NaCl and 2 mM CaCl2. 
The reaction mixture was incubated for overnight at room 
temperature, and the cleaved Bac7 (1–35) was purified 
from the reaction mixture by ion-exchange chromatogra-
phy using SP-Sepharose (GE healthcare). The column was 
equilibrated with 20 mM Tris–HCl (pH 8.0) and washed 
with 20 mM Tris–HCl (pH 8.0) containing 100 mM NaCl. 
Bac7 (1–35) was eluted with 20  mM Tris–HCl (pH 8.0) 
containing 1 M NaCl. All eluted fractions were collected 
and the Bac7 (1–35) concentration was determined at 
595 nm with use of Pierce Coomassie Plus (Thermo Fisher 
Scientific) (Bradford 1976).
Synthesis of Bac7 (1–16)
Bac7 (1–16), the N-terminal fragment from residue 1 to 
residue 16 of Bac7 (1–35), consists of Arg–Arg-Ile-Arg-
Pro-Arg-Pro–Pro-Arg-Leu-Pro-Arg-Pro-Arg-Pro-Arg, 
which has been shown to still retain one-fourth of the 
Bac7 toxicity and inhibit protein synthesis (Benincasa 
et  al. 2004; Seefeldt et  al. 2016). This peptide was com-
mercially synthesized (GenScript) and dissolved in 1× 
PBS to make a 0.2 mM stock solution.
In vitro translation inhibition assay
PURExress In Vitro Protein Synthesis kit (New England 
BioLabs) was used in this study. The gene for dihydro-
folate reductase (DHFR) was used as a positive control. 
The reaction mixture containing buffer A and buffer 
B supplied from NEB were mixed with 20  U of RNase 
inhibitor (Roche), linearlized DNA (10  ng/μl) and syn-
thetic peptide Bac7 (1–16) (10  μM) or His6-PrS2-Bac7 
(1–35) (10  μM) or water, and the reaction mixture was 
incubated for 2 h at 37 °C. Protein production was exam-
ined by SDS-PAGE followed by Coomassie blue staining.
Growth inhibition test when His6‑PrS2‑Bac7 (1–35) is 
induced in E. coli
The E. coli strain, BL21(DE3) harboring either pColdPrS2 
or pColdPrS2-Bac7 (1–35) was grown in the M9-glucose 
medium. When the OD600 reached at 0.2, 1  mM IPTG 
was added into the medium to induce the protein. As a 
negative control, the culture medium in the absence of 
IPTG was also incubated and the OD600 was monitored 
every 30 min.
The antimicrobial activity of purified Bac7 (1–35) in E. coli
The E. coli strain BL21 (DE3) was grown in the M9-glu-
cose medium and purified Bac7 (1–35) was added at the 
final concentration of 2 μM into the medium when OD600 
reached 0.2. OD600 was monitored every 30 min.
Results
The expression and purification of His6‑PrS2‑Bac7 (1–35)
Since Bac7 (1–35) is highly toxic to E. coli cells, we 
attempted to express Bac7 (1–35) fused to the C-termi-
nal end of protein S or SUMO at 15  °C. As a result, we 
were not able to observe the production of His6-SUMO-
Bac7 (1–35), while His6-PrS2-Bac7 (1–35) was produced 
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as detected at around 30-kDa position in SDS-PAGE gel 
(Fig. 1a). To further improve the expression of His6-PrS2-
Bac7 (1–35), we attempted to apply the SPP system for its 
production. Since the SPP system allows one to produce 
only a target protein without producing any cellular pro-
teins, it may help to produce His6-PrS2-Bac7 (1–35) to a 
better yield. As shown in Fig. 1a, the use of the SPP sys-
tem indeed enhanced the production of His6-PrS2-Bac7 
(1–35). Notable the use of the SPP system for the produc-
tion His6-SUMO-Bac7 (1–35) was unsuccessful, probably 
because the SUMO tag could not suppress the toxicity of 
His6-PrS2-Bac7 (1–35).
After fractionation by ultracentrifuge, His6-PrS2-
Bac7 (1–35) was fully recovered in the soluble frac-
tion (Fig.  1b). The final yield after purification using 
Ni–NTA column chromatography was determined by a 
Nano Drop spectrophotometer to be 2.5 mg from 1 l LB 
medium. Higher than 90 % purification was achieved by 
one-step Ni–NTA purification (Fig. 1b).
Purification of Bac7 (1–35) from His6‑PrS2‑Bac7 (1–35)
After treating His6-PrS2-Bac7 (1–35) with factor Xa, 
cleaved Bac7 (1–35) was purified by ion-exchange col-
umn chromatography. Since the pI value of His6-PrS2 is 
5.75 while the pI value of Bac7 (1–35) is 13.0, His6-PrS2 
and Bac7 (1–35) were readily separated by SP Sepharose. 
In addition, the sizes of His6-PrS2 and Bac6(1–35) are 21 
and 4.2 kDa, respectively, so that the size of Bac7 (1–35) 
is about one-sixth of the fusion protein. Fifty-four μg of 
highly purified Bac7 (1–35) was obtained from 360 μg of 
the fusion protein, which was about 90 % yield (Fig. 1d). 
Since 2.5 mg of His6-PrS2-Bac7 (1–35) was obtained from 
1  l LB medium, the estimated yield of Bac7 (1–35) was 
0.36 mg.
Identification of the Bac7 (1–35) fragment in His6‑PrS2‑Bac7 
(1–35)
In order to confirm the existence of the Bac7 (1–35) frag-
ment in His6-PrS2-Bac7 (1–35), His6-PrS2-Bac7 (1–35) 
a b c d
Fig. 1 The production of SUMO-Bac7 (1–35) and PrS2-Bac7 (1–35) in E. coli BL21 (DE3). a BL21 (DE3) harboring either pColdSUMO-Bac7 (1–35) 
or pColdPrS2-Bac7 (1–35) was inoculated in the 5 ml of LB medium. After OD600 reached at 0.8, the 1 mM IPTG was added, and the culture was 
incubated overnight incubation at 16 °C. The position of PrS2-Bac7 (1–35) is indicated by an arrow. BL21 (DE3) co-transformed with pACYCmazF 
and pColdPrS2-Bac7 (1–35) (SPP cells) was inoculated into 5 ml of LB medium and the culture was incubated at 37 °C. Wen the OD600 reached at 0.8, 
the culture was transferred onto ice for 5 min, followed by 1 h incubation at 16 °C. After protein induction by the addition of 1 mM IPTG, the culture 
medium was incubated for overnight at 16 °C. Lane 1, SUMO-Bac7 (1–35) before induction; lane 2, SUMO-Bac7 (1–35) after induction; lane 3, PrS2-
Bac7 (1–35) before induction; lane 4, PrS2-Bac7 (1–35) after induction; lane 5, SPP cells before induction; and lane 6, SPP cells after induction. b The 
PrS2-Bac7 (1–35) production using the SPP system and its cellular localization. The ACA-less gene for Bac7 (1–35) was expressed using pCold-PrS2 
vector together with pACYCmazF at 15 °C. Lane 1, before 1 mM IPTG was added. After inducing the PrS2-Bac7 (1–35) at 15 °C for overnight, the cells 
was collected by centrifugation and subsequently cellular fractionation was carried out; lane 2, whole cells; lane 3, cell lysate after low speed cen-
trifugation; lane 4, cell pellets after low speed centrifugation; lane 5, the soluble fraction, and lane 6, the insoluble fraction. c Cleavage of PrS2-Bac7 
(1–35) by Factor Xa protease. The 30 μg of purified PrS2-Bac7 (1–35) in 50 μl was incubated with 4 μl of factor Xa protease at 37 °C for 4 h. After incu-
bation, 10 μl of the reaction mixture was subjected to 20 % SDS-PAGE. Lane 1, PrS2 only; lane 2, PrS-Bac7 (1–35) before cleavage by factor Xa; lane 3, 
PrS2-Bac7 (1–35) after cleavage by Factor Xa; and lane M, molecular weight markers. DnaK, one of the target proteins of Bac7 (1–35), was co-purified, 
and shown by an arrow. d Bac7 (1–35) purified after from PrS-Bac7 (1–35) treated by factor Xa followed by ion-exchange column chromatography. 
The concentration of purified Bac7 (1–35) was determined by Bradford reagent, and 1.6 μg of Bac7 (1–35) was analyzed by 20 % SDS-PAGE
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thus produced was treated with Factor Xa protease 
(Fig. 1c), and the digest was analyzed by SDS-PAGE fol-
lowed by mass spectrometric analysis (Fig. 2). Note that 
since Bac7 (1–35) was fused to His6-PrS2 with a tetra-
peptide linker, Ile-Glu-Gly-Arg, the treatment of the 
His6-PrS2-Bac7 (1–35) with Factor Xa releases the intact 
Bac7 (1–35). The molecular weights (MW) of PrS2 tag 
and Bac7 (1–35) are 21.5 and 4.2 kDa, respectively. The 
theoretical values of the MW for Bac7 (1–35) is calcu-
lated to be 4207 Da, agreeing well with the MW observed. 
The peak at 10.8 kDa was probably due to the initiation 
from the internal Met residue in the gene (Fig. 2). 
The function of His6‑PrS2‑Bac7 (1–35)
Although PST is known not to interfere the function of 
the fusion partner (Kobayashi et al. 2009), we next exam-
ined the inhibitory activity of the purified His6-PrS2-Bac7 
(1–35) using a cell-free protein synthesis system (New 
England BioLabs) comparing with the inhibitory ability 
of intact fusion protein. As a positive control, the expres-
sion of dihydrofolate reductase (DHFR; 20  kDa) was 
examined in the absence and presence of PrS2. As shown 
in Fig.  3a, the addition of PrS2 did not have any effects 
on the protein synthesis. Next, the inhibitory effects were 
compared between His6-PrS2-Bac7 (1–35) and His6-PrS2-
Bac7 (1–35) treated with Factor Xa. We also synthesized 
Bac7 (1–16), which was recently reported to inhibit pro-
tein synthesis (Seefeldt et al. 2016) and used as a positive 
control for the experiment. As shown in Fig.  3b, both 
His6-PrS2-Bac7 (1–35) and His6-PrS2-Bac7 (1–35) treated 
with Factor Xa inhibited the protein synthesis as well as 
Bac7 (1–16).
The antimicrobial activity of His6‑PrS2‑Bac7 (1–35) in the 
cells
Since His6-PrS2-Bac7 (1–35) was shown to retain the 
ribosome inhibition activity, we have tested the growth 
effect of induction of His6-PrS2-Bac7 (1–35) in the cells. 
As shown in Fig. 4a, the cell growth was totally arrested 
by His6-PrS2-Bac7 (1–35) after 30 min of induction, while 
the induction of His6-PrS2 did not cause the cell growth 
arrest.
The antimicrobial activity of purified Bac7 (1–35) using E. 
coli cells
The purified Bac7 (1–35) was tested using E. coli cells. 
Bac7 (1–35) efficiently inhibited E. coli cell growth at 
2 μM after 30 min (Fig. 4b).
Discussion
The AMP production in E. coli is challenging because 
their antimicrobial activity. To suppress their toxicity, rel-
atively large tags such as GST, MBP and SUMO may be 
used, however, for the most of AMP production, SUMO 
has been widely applied and many AMPs were success-
fully expressed as functional forms (Li et al. 2011; Zhang 
et  al. 2014, 2015). The SUMO tag has been shown to 
improve protein folding and solubility, and to be used for 
protein detection (Luan et al. 2014). Thus, we attempted 
to examine if the fusion of Bac7 (1–35) to the C-terminal 
Fig. 2 Molecular weight analysis using mass spectrometry. His6-PrS2-Bac7 (1–35) was cleaved by factor Xa protease and the reaction mixture was 
diluted 25 times by the matrix solution containing sinapinic acid (10 mg/ml) in 0.1 % trifloroacetic acid and 50 % acetonitrile) and spotted on to a 
target plate (Opti-TOF 384 well insert, ABSciex) and air dried, followed by mass spectroscopic analysis by a MALDI-TOF using the positive mid-
mass linear mode from 2 to 30 kDa. Peak A (4.21 kDa) represents Bac7 (1–35) fragment, peak B (10.85 kDa) represents the PrS fragment, and peak C 
(21.68 kDa) represents the PrS2 fragment
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Fig. 3 DHFR production using cell-free expression system. a DHFR expression in the presence or absence of PrS2. Solutions A and B were mixed 
according to the manufacturer’s protocol (NEB), and the mixture was incubated as a negative control (lane 1), and DNA(10 ng/μl) of DHFR were 
added and incubated as a positive control (lane 2), DNA of DHFR (10 ng/μl) together with 0.2 mg/ml of PrS2 (10 μM) were incubated. All incubations 
were performed at 37 °C for 2 h. After the incubation, 2× SDS loading dye was added and the mixture was subjected to the 17 % of SDS-PAGE and 
the molecular weight marker was shown as lane M; b DHFR expression in the presence of PrS2-Bac7 with and without factor Xa. Solutions A and B 
from the Cell-Free system (NEB) were mixed, the reaction mixture without DNA was used as a negative control (lane 1) and the reaction mixture in 
the presence of DNA (10 ng/μl) but in the absence of proteins was used as a positive control (lane 2). Lane 3, the reaction mixture containing DNA 
(10 ng/μl) together with 10 μM of Bac7 (1–16) as a control; lane 4, the reaction mixture containing DNA (10 ng/μl) together with 10 μM of PrS2-Bac7 
(1–35) after cleavage by Factor Xa; lane 5, the reaction mixture containing DNA (10 ng/μl) together with 10 μM of PrS2-Bac7 (1–35) without cleaving 
by Factor Xa, and lane M, molecular weight marker. All the reactions were carried out at 37 °C for 2 h, After the reaction, 2× SDS loading buffer was 
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Fig. 4 Toxicity of Bac7 (1–35) in E. coli. a The toxicity of pColdPrS2-Bac7 (1–35) in E. coli. BL21(DE3) harboring either pColdP2rS or pColdPrS2-Bac7 
(1–35). The cells were grown in the M9 medium. When OD600 reached 0.2, PrS2-Bac7 (1–35) was induced by 1 mM IPTG, and OD600 was monitored 
every 30 min. The circles represent pColdPrS2 without IPTG, the triangles pColdPrS2-Bac7 (1–35) without IPTG, and the Xs pColdPrS2 in the presence 
of IPTG and the squares pColdPrS2-Bac7 (1–35). The time of the addition of IPTG is shown by an arrow. b The toxicity of purified Bac7 (1–35) in E. coli. 
The E. coli cells BL21(DE3) was grown in M9-glucose medium. When OD600 reached 0.2, purified Bac7 (1–35) was added at the final concentration of 
2 μM into the medium, and OD600 was monitored every 30 min. The time of the addition of Bac7 (1–35) is shown by an arrow
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end of SUMO could suppress the Bac7 toxicity, but the 
production of the fusion protein was not detected, indi-
cating that the SUMO tag could not suppress the toxic-
ity of Bac7 (1–35), which is known to inhibit the function 
of 70S ribosomes (Mardirossian et  al. 2014). Thus, we 
next tried protein S as a fusion tag for Bac7 (1–35). The 
Protein S from Myxococcus xanthus is known to func-
tion as an intra-molecular chaperone without severely 
affecting the function of the protein fused to it, and has 
been applied for the expression of proteins which are 
insoluble and/or difficult to be expressed (Kobayashi 
et  al. 2009, 2012). In the present study, we used two 
88-residue N-terminal domains repeated in tandem to 
the C-terminal end of which Bac7 (1–35) was fused. The 
resultant His6-PrS2-Bac7 (1–35) was indeed expressed 
well in the SPP system. In this PST-SPP system, an ACA-
less gene encoding His6-PrS2 was used as an N-terminal 
tag for Bac7 (1–35) to produce His6-PrS2-Bac7 (1–35) 
(Fig. 5). We also constructed the ACA-less His6-SUMO-
Bac7 (1–35) system. However, His6-PrS2-Bac7 (1–35) 
was expressed (Fig.  1a) while the expression of SUMO-
Bac7 (1–35) was not detected, indicating that the SUMO 
tag was not able to suppress the Bac7 (1–35) toxicity 
even with use of the SPP system. Notably, however, the 
expression of His6-PrS2-Bac7 (1–35) was rather low, pos-
sibly because protein S fusion to Bac7 (1–35) did not 
completely suppress the toxicity of Bac7 (1–35). Indeed, 
pColdPrS2-Bac7 (1–35) in M9-glucose medium was toxic 
in the presence of 1 mM IPTG (Fig. 4a).
Bac7 (1–35) has been shown to inhibit the function of 
70S ribosomes to block protein synthesis (Mardirossian 
et  al. 2014). Thus, the activity of His6-PrS2-Bac7 (1–35) 
was tested using a cell-free protein expression system 
with a synthetic peptide Bac7 (1–16) as a protein synthe-
sis inhibitor (Seefeldt et al. 2016) as a control. As shown 
Fig. 3b, the production of DHFR by the cell-free system 
was indeed inhibited by both His6-PrS2-Bac7 (1–35) and 
Bac7 (1–35) which was generated from His6-PrS2-Bac7 
(1–35) by Factor Xa treatment which resulted in a small 
amount of uncleaved His6-PrS2-Bac7 (1–35) (Fig.  2c). 
Notably, the cleavage mixture effectively inhibited the 
protein synthesis (Fig.  3b). Since the minimum inhibi-
tory concentration of Bac7 (1–35) has been reported to 
be 0.5 μM (Benincasa et al. 2004), it is assumed that there 
was an excessive amount of Bac7 (1–35) in the reac-
tion mixture to inhibit protein synthesis. The PrS2 tag is 
known not to interfere with its fusion partner (Kobayashi 
et al. 2009); for example, PrS2 fused at the N-terminal end 
of OmpR, a phosphor sensory protein, did not inhibit 
the OmpR function at all (Kobayashi et  al. 2009). Thus, 
it is not surprising to see that His6-PrS2-Bac7 (1–35) pos-
sesses an antibacterial activity in spite of the fact that the 
N-terminal part of Bac7 (1–35) has been shown to be 
crucial for the antimicrobial activity (Guida et al. 2015).
Using the SPP system, MazF cleaves at all ACA in mRNA 
while only the codon-optimized ACA-less gene for His6-
PrS2-Bac7 (1–35) remains intact. Therefore, upon induc-
tion of MazF, only His6-PrS2-Bac7 (1–35) is produced in 
MazF
PrSPrS
Protein S technology (PST) 
Target protein 
Single-Protein Production (SPP) system 
PST-SPP system 
Fig. 5 Schematic presentation of the PST-SPP system. PrS, a major spore-coat protein from Myxococcus xanthus, was directly repeated (PrS2) and 
used as a tag (PST tag) for higher expression and solubilization of a target protein. Functional assay for the target protein can be done without cleav-
ing the PrS2 from the fusion protein. A codon optimized ACA-less gene for the target protein can be expressed together with pACYCmazF, cleaving 
the ACA sequences in mRNAs, allowing the cells to produce the only target gene from its ACA-less mRNA (the SPP system; Suzuki et al. 2005). Note 
that the gene for PrS2 is also codon-optimized for E. coli and designed to be ACA-less without altering the amino acid sequence. Since the PrS2 tag 
partially suppresses the antimicrobial activity of a cloned peptide or protein, the use of the PST-SPP system allows one to produce toxic peptides 
and proteins in E. coli and also to perform their functional assay using the cell lysate
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the cells (Fig. 5). Notably, in the SPP system, all the cellular 
mRNAs containing ACA sequences are digested by MazF, 
so that cell growth is completely arrested allowing the 
production of only the target protein from the ACA-less 
mRNA in the growth-arrested cells. In this manner, toxic 
proteins can still be produced as far as they do not inhibit 
ATP production and protein synthesis. Previously, we have 
demonstrated that it is possible to completely replace all 
arginine residues in a protein with canavanine, a highly 
toxic analogue of arginine using the SPP system, since the 
incorporation of canavanine into any other cellular pro-
teins is well suppressed (Suzuki et al. 2006; Mao et al. 2009; 
Ishida et al. 2013). In the present paper, we combine both 
PST and SPP technologies (PST-SPP technology) to suc-
cessfully express His6-PrS2-Bac7 (1–35).
In this study, we demonstrated to obtain 90  % pure 
His6-PrS2-Bac7 (1–35) by one-step purification. In 
addition, Bac7 (1–35) was readily purified from His6-
PrS2-Bac7 (1–35) treated by factor Xa followed by ion 
exchange column chromatography using SP-Sepharose, 
since the pI value of His6-PrS2 is 5.75 while that of Bac7 
(1–35) is 13.0. We were able to obtain highly pure Bac7 
(1–35) with approximately 90  % yield. It is also impor-
tant to note that since Bac7 (1–35) does not have any 
aromatic residues, the protein concentration should be 
determined by ninhydrin or the Bradford assay (Bradford 
1976). While the chemical synthesis of long AMPs such 
as Bac7 (1–35) is highly expensive, the technology devel-
oped in the present paper will greatly reduce the cost of 
the AMP production.
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